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Abstract
Aims—Active targeted transport of the nanoformulated redox enzyme, catalase, in macrophages
attenuates oxidative stress and as such increases survival of dopaminergic neurons in animal
models of Parkinson’s disease. Optimization of the drug formulation is crucial for the successful
delivery in living cells. We demonstrated earlier that packaging of catalase into a polyion complex
micelle (‘nanozyme’) with a synthetic polyelectrolyte block copolymer protected the enzyme
against degradation in macrophages and improved therapeutic outcomes. We now report the
manufacture of nanozymes with superior structure and therapeutic indices.
Methods—Synthesis, characterization and therapeutic efficacy of optimal cell-based
nanoformulations are evaluated.
Results—A formulation design for drug carriers typically works to avoid entrapment in
monocytes and macrophages focusing on small-sized nanoparticles with a polyethylene glycol
corona (to provide a stealth effect). By contrast, the best nanozymes for delivery in macrophages
reported in this study have a relatively large size (~200 nm), which resulted in improved loading
capacity and release from macrophages. Furthermore, the cross-linking of nanozymes with the
excess of a nonbiodegradable linker ensured their low cytotoxicity, and efficient catalase
protection in cell carriers. Finally, the ‘alternatively activated’ macrophage phenotype (M2)
utilized in these studies did not promote further inflammation in the brain, resulting in a subtle but
statistically significant effect on neuronal regeneration and repair in vivo.
Conclusion—The optimized cross-linked nanozyme loaded into macrophages reduced
neuroinflammatory responses and increased neuronal survival in mice. Importantly, the approach
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for nanoformulation design for cell-mediated delivery is different from the common requirements
for injectable formulations.
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The restriction of macromolecules entry to the brain is a major impediment to the
development of new treatment strategies for neurodegenerative and neuroinfectious
diseases, which include Parkinson’s (PD) and Alzheimer’s diseases, meningitis,
encephalitis, prion disease, HIV-associated neurocognitive disorders [1,2] and stroke [3,4].
The pathobiology of these disorders have an inflammatory component in common [5], with
production of reactive oxygen species (ROS) and proinflammatory factors, and
consequential neurodegeneration [6–9]. The means to effectively treat such disorders by
attenuating ROS production has met with limited success based, in part, on inefficient
enzyme delivery to affected brain regions and across the blood–brain barrier (BBB) [10]. To
this end, our own works have sought to improve brain delivery of one of the most potent in
nature redox enzymes, catalase [11–1 4]. This has been based on the concept that
immunocytes readily home to the sites of inflammation and can be used as vehicles for CNS
drug delivery of antioxidant enzymes [15]. Active targeted drug transport to disease sites by
the cell carriers offers several advantages, which include: improved drug efficacy, prolonged
half-lives, time-controlled drug release, and diminished immunogenicity and cytotoxicity. In
addition to drug transport across the BBB, the efficient delivery of antioxidants to the brain
endothelium, a substantive ROS source [16], could also be beneficial for a range of
neurologic disease-combating therapies [17–19].
Our laboratory sought to optimize the structure of catalase nanoparticles for cell-mediated
delivery and therapeutic gain. We proposed to incorporate catalase in the block ionomer
complexes (BICs) with a cationic block copolymer, poly(ethyleneimine) (PEI)–polyethylene
glycol (PEG; PEI–PEG), termed ‘nanozyme’, which protected the enzyme within
macrophages [13]. Preservation of catalase enzymatic activity in macrophages by such
complexes was, in part, due to the decreasing of acidification of the cell’s endocytic
compartments by the amino groups on the surface of the nanoparticles. This inhibited the
protease activity and decreased the drug degradation in the host cells [20]. Here, we report
further developments of drug nanoformulations for delivery in living cells. Contrary to a
common approach for injectable drug formulations, the optimal particles were greater in size
and stabilized by a nonbiodegradable cross-linker (Figure 1). This resulted in their higher
loading capacity for macrophages, greater release and superior preservation of catalase
enzymatic activity. Such nanozymes displayed significant therapeutic efficacy in in vitro
and in vivo models of neuroinflammation. These results are in accordance with our prior
findings regarding the cross-linking of BICs with another antioxidant enzyme, superoxide
dismutase 1, which resulted in improved enzyme stability in the blood and brain [21]. Our
ultimate goal is to obtain injectable catalase nanoformulations that may be loaded into cell
carriers directly into the bloodstream and delivered to disease sites by active targeted
transport in macrophages.
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Catalase from bovine liver was purchased from Calbiochem (CA, USA). Bis-
(sulfosuccinimidyl)suberate sodium salt (BS3), 3,3’-dithiobis-(sulfosuccinimidyl
propionate) (DTSSP), 6-hydroxydopamine (6-OHDA), lipopolysaccharides (LPS), PEI (2K,
branched, 50% aqueous solution), rhodamine isothiocyanate, and Triton™ X-100 were from
Sigma-Aldrich (MO, USA). Methoxypolyethylene glycol epoxy was from Shearwater
Polymer Inc. (AL, USA). PEI (2K)–PEG (10K) was synthesized as described previously by
conjugation of PEI and methoxypolyethylene glycol epoxy [11]. 3H-labeled catalase was
custom synthesized by PerkinElmer Life (MA, USA). IFN-γ was purchased from Peprotech
Inc. (NJ, USA). A XenoLight™ RediJect D-Luciferin Ultra inflammation probe was
purchased from Caliper LifeSciences (MA, USA). A description of the different antibodies
(Abs) for catalase intracellular localization studies can be found in the Supplementary
Material (see online at www.futuremedicine.com/doi/suppl/10.2217/NNM.13.115).
Assembling & cross-linking catalase nanozymes
A description of nanozymes used in this study is presented in Table 1. The BICs were
produced by mixing catalase and a block copolymer (PEI–PEG) that bind electrostatically to
each other and form nanoparticles with an enzyme–polyion complex core and PEG corona.
Catalase and the block copolymer were separately dissolved in phosphate-buffered saline
(PBS) at room temperature. Precalculated volumes of the block copolymer solution (0.25
mg/ml) were added drop-by-drop to the enzyme solution (0.5 mg/ml) to achieve the desired
charge ratio (charge ratio [Z] = 2–9). The Z was calculated by dividing the number of amino
groups in PEI–PEG protonated at pH 7.4 [22] by the total amount of glutamate and aspartate
in the catalase. The mixture was supplemented with a six-times excess of either a
biodegradable linker (DTSSP) or nonbiodegradable linker (BS3; with respect to catalase
charges), incubated overnight at 4°C, and unreacted cross-linker was removed by desalting
using NAP-10 Columns (GE Healthcare Bio-Sciences Corp., NJ, USA). Obtained
nanozymes were characterized by electrophoretic retention, dynamic light scattering (DLS),
nanoparticle tracking analysis and atomic force microscopy (AFM). A description of these
methods can be found in the Supplementary Material.
Macrophage isolation, differentiation & cultivation
Bone marrow-derived macrophages (BMMs) were extracted from the femurs of 6–7-week-
old C57Bl/6 male mice according to previously published protocols [23] and cultured for
12–14 days in DMEM medium (Invitrogen, CA, USA) supplemented with 1000 U/ml
macrophage colony-stimulating factor (MCSF), a generous gift from Wyeth Pharmaceutical,
MA, USA. RAW 264.7, a mouse macrophage cell line, was purchased from the American
Type Culture Collection (VA, USA; catalog # TIB-71), and cultured in the DMEM
supplemented with 10% fetal bovine serum. Human monocyte-derived macrophages
(HMDMs) were obtained from the leukopaks of healthy donors, purified by countercurrent
centrifugal elutriation [24] and cultured with MCSF [23].
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To promote specific differentiation of RAW 264.7 macrophages, the cells were cultured in
the presence of: IL-4 (to promote the M2 anti-inflammatory subtype), or IFN-γ and LPS (to
obtain the M1 proinflammatory subtype). For M2 subset differentiation, macrophages were
supplemented with IL-4 (40 ng/ml) for 48 h. For M1 subset differentiation, the cells were
cultured in a mixture of IFN-γ (20 ng/ml) and LPS (100 ng/ml) for 48 h. Following
incubation, the media was replaced with a mixture of: Abs to the mannose receptor (M2 type
marker, anti-CD 206; 1 µg/ml; BD Biosciences, CA, USA), and Abs to CD 86 (M1 type
marker, anti-CD 86; 2 µg/ml; BD Biosciences). The cells were incubated with the Abs for 1
h, washed, fixed and examined by confocal microscopy as described below (CD 86: λ = 405
nm; and CD 206: λ = 647 nm). An overexpression of specific markers related to the M1 or
M2 subset of macrophages upon cell differentiation was confirmed by FACS.
Measures of nanozyme activity
The catalase activity of the obtained nanozymes in a cell-free system was measured using
hydrogen peroxide decomposition [13]. The initial catalase activity was 38,000 U/mg
protein. Next, the effect of cross-linking on the stability of the enzyme in BIC was examined
upon incubation of different nanozymes (0.5 mg/ml catalase) with trypsin (10–5 M) or
pronase (2 × 10−1 mg/ml) for 3 h at 37°C. Following incubation, the aliquots were subjected
to catalytic activity assessment as described before. The stability of catalase was expressed
in residual activity versus initial activity of nanozyme.
For evaluation of the activity of catalase released from the cell carriers, RAW 264.7
macrophages were loaded with different nanozyme formulations for 2 h, then the loading
solutions were washed with PBS, and fresh complete media with serum was added to the
cells. Following different periods of time, the media was collected and the antioxidant
activity of the enzymes released from macrophages was assayed as described before. The
concomitant media collected from nonloaded macrophages was examined in the control
experiments, and the activity of released endogenous catalase was subtracted from the
samples with nanozyme-preloaded macrophages.
Nanozyme accumulation & release
First, cytotoxicity of different nanozyme formulations in BMMs or RAW 267.4
macrophages were evaluated using a standard 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide assay [25], as described in [13]. A tracer dose of 3H-labeled catalase (4
µCi, 2 µl) was mixed with nonlabeled catalase solution (0.03 mg/ml), supplemented with
PEI–PEG block copolymer and cross-linked (Cl) to obtain nanozyme, as described before.
For accumulation studies, RAW 264.7 macrophages grown on 24-well plates (2.5 × 106
cells/plate) were treated with the 3H-labeled catalase alone or various nanozyme
formulations in the assay buffer for different periods of time in the absence of serum [26,
27]. The concentration of catalase was kept the same in all samples (4 µCi/ml). After
incubation, the cells were washed with PBS and solubilized in Triton X-100 (1%). For
release studies, the cells were loaded with nanozymes for 2 h, washed with PBS and then
incubated in fresh media for various times. A total of 100 µl of the cell concomitant media
was then placed into 4 ml of a liquid scintillation cocktail, and the radioactivity levels were
determined using a Tri-Carb® 4000 (Packard Bioscience; now PerkinElmer) scintillation
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counter. Assuming that radioactivity levels corresponded to the amount of 3H-labeled
nanozyme, the obtained values were normalized for total cell protein content and expressed
in ng of catalase per mg of total protein for loading experiments, and ng of catalase per ml of
media.
Confocal microscopy
To study intracellular localization, the catalase was labeled with the Alexa Fluor® 680 or
Alexa Fluor 488 Protein Labeling Kit (Invitrogen); the PEI or PEI–PEG were labeled with
rhodamine isothiocyanate [11]. The intracellular localization studies were performed in
HMDMs due to the specificity of the Abs used for different intracellular compartments
staining. HMDMs grown in the chamber were treated with labeled Cl-6-BS3 (0.2 mg/ml) in
assay buffer for various periods of time (5–60 min) at 37°C [28]. A detailed description of
these evaluations can be found in the Supplementary Material.
To evaluate the transport of the macrophages into the brain with inflammation, RAW 264.7
macrophages were transduced with green fluorescent protein (GFP) firefly luciferase viral
vector, as described in [29]. To eliminate nontransduced cells, macrophages were selected
against puromycin (0.5 µg/ml). GFP-overexpressing macrophages were injected into 6-
OHDA-intoxicated BALB/C mice on day 21 after intracranial (ic.) injection of the toxin. A
total of 24 h later, mice were sacrificed and perfused with PBS and 4% paraformaldehyde.
Brains were frozen, sectioned with a cryostate (10 µm thick) and examined by confocal
microscopy (60× magnification). Healthy mice without brain inflammation (with PBS ic.
injections) were used as a control group. The glass slides (five slides per brain) were
sequentially treated with primary monoclonal mouse anti-CD11b Abs (BD Pharmingen, NJ,
USA), the Abs defining macrophages; and secondary fluorescently labeled anti-Mouse-IgG-
atto 647N (red; Sigma-Aldrich; 1:200 dilution), and then analyzed by confocal fluorescence
microscopy.
For evaluation of catalase activity in the mouse brain, tissues from control animals were ic.
injected with PBS or 6-OHDA, as described later, or PD mice were injected with 6-OHDA
following intrajugular vein (intravenous; iv.) injection of BMM loaded with nanozyme (5 ×
106 cells/mouse in 100 µl PBS) 48 h later. A total of 7 days after BMM treatment, animals
were anesthetized with a ketamine/xylazine anesthetic cocktail and perfused transcardially
with ice-cold PBS for 5 min. Ventral midbrain areas were dissected and placed in an ice-
cold assay buffer (50 mM potassium phosphate buffer; pH 7.0), homogenized and
centrifuged at 4000 rpm. Collected supernatant samples were analyzed for catalase activity
using the Catalase Assay Kit (Cayman Chemical Company, MI, USA). Enzyme activity was
expressed in nmol/min/ml.
Amplex® Red dye fluorescence assay
The decomposition of ROS in Cath.a neurons stimulated with 6-OHDA by different
nanozymes released from preloaded macrophages was measured by fluorescence, as
described before [11]. The effect of the supernatants collected from nonloaded macrophage
ROS decomposition was evaluated with the control experiments. Specific details of this
experiment can be found in the Supplementary Material.
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Bioimaging & infrared spectroscopy of neuroinflammation
C57Bl/6 male mice were used in the in vivo image visualization and infrared spectroscopy
(IVIS) experiments (five mice per group). The animals were treated in accordance with the
Principles of Animal Care outlined by the US NIH and approved by the Institutional Animal
Care and Use Committee of the University of Nebraska Medical Center (USA). For
induction of brain inflammation, mice were ic. injected with LPS solution, as described in
[14]. Specific details of these procedures can be found in the Supplementary Material. A
total of 24 h after LP intoxication, animals were injected iv. with macrophages (5 × 106
cells/mouse in 100 µl PBS) preloaded with Cl nanozyme (Cl-6-BS3). Saline-treated animals,
which were intoxicated with LPS 24 h before the treatment, were used in the control group.
A total of 10 min before luminescent imaging (exposure time: 10 min), each animal received
an intraperitoneal injection of XenoLight RediJect Inflammation probe. Animals were
imaged at 1–30 days following the treatment using an IVIS® 200 Series imaging system
(Xenogen Co., now Caliper LifeSciences). The chemoluminescent signal was quantified by
Living Image® 2.50 software (Caliper LifeSciences) and presented as a radiance ratio of
treated animal versus 24 h after LPS injection.
Immunohistochemical & stereological analyses
6-OHDA-intoxicated mice (six animals per group) were iv. injected either with PBS,
nanozyme-preloaded macrophages (5 × 106 cells/mouse/100 µl), macrophages preloaded
with naked catalase, macrophages alone, or Cl nanozyme alone (Cl-6-BS3; 0.5 mg/ml
catalase) 48 h after intoxication. Healthy, nonintoxicated animals were ic. injected with PBS
instead of 6-OHDA and used in control groups. A total of 5 weeks later, animals were
sacrificed, perfused according to standard perfusion protocol, brains were removed, and
immunohistochemical analysis was performed, as described in [29]. A detailed description
can be found in the Supplementary Material.
Statistical analysis
For all experiments, data are presented as the mean ± the standard error of the mean. Tests
for significant differences between the groups were performed using a one-way analysis of
variance with multiple comparisons (Fisher’s pairwise comparisons) using GraphPad
Prism® 6.0 (GraphPad software, CA, USA). A minimum p-value of 0.05 was chosen as the
significance level for all tests.
Results
Nanozyme manufacture & characterization
Catalase has a net negative charge at neutral pH (phosphate buffer, pH 7.4). The BICs at
various charge ratios (Z = 2–9) were produced by mixing the enzyme and cationic block
copolymer PEI–PEG solutions, which bind electrostatically to each other, forming
nanoparticles with the enzyme–polyion complex core and PEG corona. The cross-linking of
the polyion complexes using nonbiodegradable (BS3) or biodegradable (DTSSP) linkers
was confirmed by electrophoresis under denaturizing conditions and they were then
transferred to nitrocellulose membranes for western blot (Supplementary Figure S1). Non-Cl
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BIC was unstable under denaturing conditions, resulting in protein release and subunit
dissociation, similar to catalase alone. Cross-linking of BIC with both BS3 and DTSSP
linkers retarded catalase electrophoretic mobility, suggesting that cross-linking afforded
resistance to protein denaturation. It is worth noting that no free catalase was present in
either Cl nanozyme preparation, suggesting that all catalase was incorporated into BIC and
conjugated with PEI–PEG.
The hydrodynamic size and zeta-potential of nanozymes were determined by DLS (Table 2).
Particles of naked catalase were approximately 13 nm in size with a low polydispersity
index. This was close to the theoretical diameter (12.5 nm) of a single protein globule
calculated from the molecular mass of the enzyme [30]. The formation of BICs (non-Cl
nanozymes) resulted in slightly increased particle size, especially at Z = 2. Significantly
larger aggregates were recorded for the Cl nanozymes, especially for BICs obtained with
nonbiodegradable linkers (BS3). This was probably due to the cross-linking of several
particles together, including bridging them through PEI–PEG that would not otherwise
incorporate into BICs. It is worth noting that maximal particle size was recorded at Z = 6,
with a mild, but statistically significant, decrease at Z = 9. The zeta-potential values
decreased after the cross-linking, which may be indicative of consumption of the protein
and/or PEI amino groups that reacted with the cross-linking reagents. Finally, a low
polydispersity index for both Cl nanozymes indicates absence of small particles
corresponding with the size of free catalase.
The size and polydispersity of the obtained nanoparticles were confirmed by a NS500
Nanoparticles Tracking Analysis system (NanoSight, Wiltshire, UK). This method allows
the detection of a fraction of small particles in the presence of considerably greater particles,
which is not detectable by DLS. The mean particle size for Cl-6-BS3 was 170 nm
(Supplementary Figure S2), which correlated with the DLS results (Table 2).
The molecular weight of the obtained nanoparticles was determined using static light
scattering analysis. For this purpose, solutions of Cl-6-BS3 were prepared at a range of
concentrations (0.022–0.35 mg/ml), and the values of apparent molecular weight (inverse of
molecular weight) obtained by light scattering were plotted over the range of nanoparticle
concentrations (Supplementary Figure S3). The calculated molecular weight of the particles
that was determined by the extrapolation of the linear dependence to zero concentration was
16,000 kDa, suggesting approximately 15 molecules of catalase in the particle.
AFM images confirmed the presence of small spherical particles for non-Cl nanozyme (non-
Cl-6) and larger aggregates for the Cl nanozymes (Cl-2-BS3 and Cl-6-BS3) (Supplementary
Figure S4). Consistent with DLS studies, the increase of PEI–PEG amount in BIC resulted
in bigger particles. Therefore, AFM images provide average diameters and heights for non-
Cl-6 (diameter: 11.5 ± 0.03 nm; height: 2.4 ± 0.08 nm), Cl-2-BS3 (diameter: 61.7 ± 0.07
nm; height: 29.8 ± 0.02 nm) and Cl-6-BS3 (diameter: 82.1.7 ± 0.08 nm; height: 36.8 ± 0.02
nm). Notably, as commonly observed for BICs, the sizes determined by AFM were smaller
than those determined by DLS. This is typical for such systems, since AFM images are
obtained in the absence of the solvent, while DLS determines the hydrodynamic diameter
(i.e., the size of the swollen particles) [31]. AFM suggested that the particles of non-Cl-6
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and Cl-2-BS3 have a common spherical morphology, while Cl-6-BS3 displayed a higher
fraction of nonspherical formations (Supplementary Figure S4). The latter may be due to the
cross-linking of multiple BIC particles, with the excess of PEI–PEG polymer present at Z =
6 serving as a particle ‘bridge’.
Effect of cross-linking on nanozyme cytotoxicity, loading & release
Covalent binding of PEI–PEG to catalase considerably diminished the toxicity of
nanozymes in RAW 264.7 macrophages and BMMs (Supplementary Table S1). Although
non-Cl nanozymes showed significant toxicity in RAW 264.7 macrophages (IC50: 0.3 ± 0.1
and 0.1 ± 0.1 mg/ml protein for non-Cl-2 and non-Cl-6, respectively), all Cl nanozymes
were not toxic over all ranges of concentrations (up to 1 mg/ml). It is worth noting that
BMMs were more resilient to the cytotoxic effects of nanozymes and did not show any
decreases in survival for both Cl and non-Cl nanozymes (Supplementary Table S1).
Next, for optimal for cell-mediated delivery, nanozymes should have a high loading capacity
in macrophages and a sustained release at the disease site. Herein, we examined the effects
of cross-linking on nanozyme accumulation and release in RAW 264.7 macrophages. First,
the accumulation kinetics of some representative nanozymes, shown in Supplementary
Figure S5a, suggested a rapid uptake. Consistent with our previous work [13], formation of
BICs significantly reduced the amount of non-Cl nanozymes taken up by the cells compared
with ‘naked’ catalase (Supplementary Figure S5A), possibly due to the effect of the PEG
corona. However, the cross-linking of nanozymes significantly improved uptake in
macrophages, especially for larger particles (Cl-6-BS3; Supplementary Figure S5B). Similar
dependences were found in BMMs. Therefore, the cross-linking of nanozymes with both
biodegradable and nonbiodegradable linkers (Cl-6-DTSSP and Cl-6-BS3, 30-min time
point) increased their accumulation in the cells 1.5- and 2.3-times, respectively. Overall, the
nanozyme loading capacity in macrophages exponentially increased with the particle size
(Figure 2; squares). Preloaded RAW 264.7 macrophages released catalase into the media for
at least 7 days (Supplementary Figure S6A). Consistent with these studies, cross-linking of
nanozymes resulted in significant increases in catalase release from RAW 264.7
macrophages (Supplementary Figure S6B), which also correlated with nanozyme size
(Figure 2; circles).
Effect of cross-linking on the preservation of catalase activity in the cell carriers
Based on these results, we selected nanozymes with a greater size (Cl-6-DTSSP and Cl-6-
BS3) for further experiments. First, we examined catalase activity for each formulation in a
cell-free system. It was demonstrated earlier that the incorporation of catalase into BIC with
PEI–PEG at pH 7.4 did not significantly affect the enzyme activity. Here, we confirmed that
no changes in the enzymatic activity of catalase were detected upon complex formation, as
well as cross-linking with BS3 or DTSSP (Supplementary Table S2). Catalase in the
obtained BICs was stable in water solutions; no decreases in the enzymatic activity were
recorded for up to 7 days. Furthermore, the cross-linking of catalase with a block copolymer
increased stability of catalase against a mixture of proteinases (trypsin and pronase)
(Supplementary Figure S7). Therefore, 90–98% of the enzyme was preserved in nanozyme
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formulations, Cl-6-DTSSP and Cl-6-BS3, when only 10% of naked catalase and 50–80% of
non-Cl nanozyme was active after incubation with proteinases.
Finally, preservation of enzymatic activity in different catalase formulations as released
from RAW 264.7 macrophages was evaluated by spectrophotometry (Figure 3A). Contrary
to the free catalase that was completely inactivated inside macrophages after 4 h,
macrophages preloaded with non-Cl-6 released active enzyme for at least 52 h. The cross-
linking of nanozymes further increased the stability of catalase against degradation in the
cells, especially at later time points (52–168 h), resulting in prolonged and sustained release
of active catalase from macrophages. Stabilization with nonbiodegradable linker (Cl-6-BS3)
protected catalase activity slightly better than with biodegradable linker (Cl-6-DTSSP). A
similar pattern was demonstrated for Cl nanozymes released from BMMs. Therefore,
enzymatic activity of Cl-6-BS3 released from preloaded BMMs over 24 h was 2.5-times
greater than the activity of the corresponding non-Cl nanozyme, non-Cl-6.
To assess the antioxidant capacity of the catalase nanoformulations in an in vitro model of
PD, RAW 264.7 macrophages preloaded with different nanozymes (Cl-2-BS3 and Cl-6-
BS3) were incubated for 24 h in Krebs-Ringer buffer, and the concomitant media was
collected and added to neurons treated with 6-OHDA. The amount of hydrogen peroxide
produced by activated neurons and decomposed by catalase released from the cell carriers
was assessed using Amplex® Red assay (Life Technologies, NY, USA) (Figure 3B). A
greater effect was observed by Cl nanozymes that was consistent with their ability to
preserve enzyme activity in the carrier cells (Figure 3A). Furthermore, catalase activities in
nanozymes obtained at a higher Z (Cl-6-BS3) were protected in macrophages to a greater
extent than at a lower Z (Cl-2-BS3). The supernatants collected from nonloaded
macrophages had no effect on the hydrogen peroxide level. Together, this study suggests
that the Cl nanozyme at Z = 6 was the most efficient in attenuating oxidative stress in an in
vitro PD model. This is probably a result of both ROS inactivation in the neuronal media, as
well as nanozyme efficient transport from cell carriers to the target cells.
Using ‘alternately activated’ macrophages
The possibility of using a particular subset of macrophages that would not cause additional
inflammation at the disease site (as it is known for classically activated macrophages [32]),
but would rather have neuroregenerative properties was investigated. For this purpose, RAW
264.7 macrophages were cultured in the presence of: IL-4 (for the M2 anti-inflammatory
subtype); IFN-γ and LPS (for the M1 proinflammatory subtype); or MCSF as described in
the ‘Materials & Methods’ section. The obtained subsets of macrophages were characterized
by confocal microscopy (Figure 4A). Macrophages differentiated in the presence of IFN-
γ/LPS demonstrated considerable expression of CD 86, and low, if any, levels of the
mannose receptor (Figure 4A,i), which is indicative for the classically activated
proinflammatory M1 subtype. By contrast, RAW 264.7 macrophages differentiated in the
presence of IL-4 or MCSF showed high expression levels of the mannose receptor, and low,
if any, expression of CD 86 (Figure 4A,iii), which is indicative for ‘alternately activated’
anti-inflammatory macrophages. The obtained results were confirmed by FACS. Indeed,
treatment of macrophages with IFN-γ/LPS mixture resulted in upregulation of CD 86
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expression, while treatment with IL-4 increased the expression levels of the mannose
receptor (Supplementary Table S3). Next, R AW 264.7 macrophage responses to
inflammatory signals representing the microenvironment at the disease tissues was
examined in vitro. The macrophages differentiated with or without MCSF were
supplemented with IFN-γ and LPS (to stimulate proinflammatory responses), and the
amount of ROS in the concomitant media was measured by Amplex Red assay (Figure 4B).
Cells cultured without MCSF released approximately four-times more ROS in the presence
of IFN-γ and LPS. By contrast, macrophages grown in the presence of MCSF produced
significantly lower levels of ROS. This indicates that a particular subset of alternatevly
activated macrophages (M2) can sustain their anti-inflammatory functions even at the
inflammation site and be utilized for targeted drug delivery, while limiting secondary
inflammatory-mediated injury.
Intracellular localization of nanozyme in macrophages
It has long been demonstrated that incorporation of DNA molecules into BICs with PEI–
PEG results in the protection of DNA from nuclease degradation in biological milieu [22].
Similarly, we posit that the preservation of the active catalase by incorporation into BIC may
be, at least in part, due to steric protection (masking) of the enzyme from proteolytic
enzymes by polycation, as well as through PEI–PEG interactions with membranes, and
change in ion currents, membrane potential and proton gradients, resulting in the decreases
in acidification of endosomal compartments. The nanozyme cross-linking may further
enhance this protective effect. To prove this hypothesis, we labeled catalase with Alexa 488
and PEI–PEG with rhodamine isothiocyanate, prepared non-Cl (non-Cl-6) or Cl (Cl-6-BS3)
nanozymes, and studied their intracellular localization in BMMs by confocal microscopy
(Figure 5). The cells were grown in the presence of MCSF as described in the ‘Materials &
Methods’ section. As expected, the cross-linking of BIC (Cl-6-BS3) resulted in practically
total colocalization of the polymer and catalase inside macrophages (Figure 5D). The block
copolymer from non-Cl-6 was partway dissociated, resulting in the appearance of PEI–PEG
fluorescence separate from that of catalase (Figure 5C). However, in this case, considerable
colocalization of the labeled catalase and block copolymer still remained, which was
consistent with the partial stabilization effect of non-Cl BICs. Control cells loaded with
catalase alone are shown in Figure 5A. In this study, we also used BIC with PEI
homopolymer (Z = 6) to assess whether the absence of a PEG corona could affect
localization of the catalase and polycation in macrophages. Interestingly, the non-Cl polyion
complex of homopolymer PEI was completely dissociated in macrophages, with PEI
localizing close to the cell surface and catalase in vesicular compartments and/or cytoplasm
(Figure 5B). This resulted in acidification of endosomal compartments, which was shown
with pH-sensitive dye, LysoSensor™ Yellow/ Blue (Life Technologies), activation of
proteases and fast catalase degradation [13]. Therefore, the presence of PEG chains on the
surface on the nanozyme plays a stabilization role of the polyion complex inside the cells,
possibly by preventing interactions of the polycation with negatively charged cell
membranes that may lead to dissociation of non-Cl BIC.
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Nanozyme cross-linking affects intracellular trafficking in macrophages
To examine nanozyme intracellular localization in the living cells, colocalization with main
cellular compartments was evaluated by staining intracytoplasmic organelles, which
included acidified endosomes, endoplasmic reticulum (ER) and mitochondria (Figure 6).
Fluorescently labeled catalase was used in Cl nanozyme Cl-6-BS3. The HMDMs grown in
the presence of MCSF were incubated with Cl-6-BS3 for various periods of time, washed
and stained with markers for different intracellular compartments. Microphotographs
demonstrated substantial colocalization of the nanozyme with LysoTracker® (Life
Technologies; 28–39% colocalization; Figure 6 & Supplementary Table S3), and to a lesser
degree with ER (1–20% colocalization; Figure 6 & Supplementary Table S3) and
MitoTracker® (Life Technologies; 12–16% colocalization; Figure 6 & Supplementary Table
S4). It is worth noting that Cl-6-BS3 was relocated from acidic endosomes to other cellular
compartments at later time points (30–60 min; Supplementary Table S4). LysoTracker
allows the examination of nanoparticle intracellular localization in live cells [33]. However,
the marker stains all acidic compartments, including lysosomes, late endosomes and, to
some extent, recycling endosomes. To study nanozyme localization in greater detail, specific
staining with Abs to early, lat or recycling endosomes and lysosomes was performed in
fixed human macrophages (Supplementary Figure S8 & Table S4). The Cl nanozyme Cl-6-
BS3 first accumulated largely in early and late endosomes as determined by fluorescein
isothiocyanate-conjugated mouse antibodies to EEA1 to early endosomes (BD Biosciences;
5–15% colocalization; Supplementary Figure S8 & Table S4) and mouse monoclonal
antibodies to RAB 7 to late endosomes (Abcam, MA, USA; 7–17% colocalization;
Supplementary Figure S8 & Table S4) immunostaining, respectively, and then was
reshuffled to lysosomes (6.5–22% colocalization with LAMP1; to late endosomes
Supplementary Figure S8 & Table S4). In contrast to a preferential compartmentalization of
non-Cl BIC within recycling endosomes reported earlier [34], there was very little
colocalization of Cl nanozyme with recycling endosomes as determined by Rab 11 Abs (3–
10% colocalization; Supplementary Figure S8 & Table S4). It indicates that the cross-
linking of catalase nanozymes altered their trafficking and intracellular localization in
macrophages, resulting in nanozyme escape from endosomal compartments (in particular,
recycling endosomes) into cytoplasm, and accumulation in ER and mitochondria with partial
localization in lysosomes (Figure 7). It is worth nothing that a portion of nanozyme
transferred to cytosol may be released inside exosomes, extracellular organelles secreted by
macrophages, as was demonstrated in [34].
Macrophages accumulate in an inflamed mouse brain
To examine whether macrophages reach the brain tissues, 6-OHDA-intoxicated mice were
iv. injected with GFP-expressing RAW 264.7 macrophages. To track the cells in the mouse
brain, macrophages were transduced with GFP firefly luciferase viral vector to overexpress
the chimeric protein consisting of GFP and firefly luciferase (Figure 8A). Transduced
macrophages were cultured for 5 days in the presence of MCSF to produce M2 ‘alternately
activated’ macrophages, and then systemically administered into PD mice at the peak of
inflammation (21 days after 6-OHDA intoxication). A total of 24 h later, mice were
sacrificed and perfused as described in the ‘Materials & Methods’ section. Confocal images
of brain slides taken from 6-OHDA-intoxicated mice demonstrate significant amounts of
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GFP-expressing macrophages in the midbrain (Figure 8B). Colocalization of GFP-
expressing macrophages (green) and Abs to CD11b (red) manifested in yellow staining
confirmed that the accumulated cells were in fact macrophages. It is worth nothing that
macrophages were not detected in the brain of healthy mice (Figure 8C). Furthermore,
catalase activity in the ventral midbrain of mice with brain inflammation was evaluated.
Significant increases in the enzyme activity (p < 0.05) were found in PD mice treated
systemically with macrophages loaded with nanoformulated catalase (15.8 ± 0.6
nmol/min/ml) compared with PD mice treated with PBS (7.8 ± 0.5 nmol/min/ml), or control
healthy mice (7.9 ± 0.9 nmol/min/ml). Taken together, this indicated that catalase-loaded
macrophages were able to cross the BBB and deliver their payload to the inflamed tissues.
Nanozyme-loaded BMMs reduce neuroinflammation
Linkages between neuroinflammation and nigrostriatal degeneration have been reported
[35]. Therefore, attenuation of inflammation could serve to protect dopaminergic neurons in
disease [8,9]. To examine whether macrophages preloaded with Cl nanozyme can reduce
brain inflammation, IVIS studies were conducted. For this purpose, C57BL/6 mice were
stereotactically injected with LPS into the substantia nigra pars compacta (SNpc) to produce
inflammation, and then 24 h later one group was iv. injected with BMMs preloaded with the
selected Cl-6-BS3 (Figure 9A,iia: whole body, Figure 9A,iib: head). Another group of LPS-
intoxicated mice was iv. injected with PBS and used as a control. IVIS images of both
groups were taken over 22 days. The chemiluminescent signal was quantified and presented
as a radiance ratio of treated animal versus 24 h after LPS injection at various time points
(Figure 8A). LPS ic. injections caused more than a threefold increase in brain inflammation
levels of the control group. The Cl nanozyme administered in macrophages considerably
decreased neuroinflammation in LPS-intoxicated mice. The prolonged anti-inflammatory
effect was recorded more than 3 weeks after LPS intoxication. This signified the ability of
nanozyme-loaded macrophages to reduce oxidative stress.
Next, potent anti-inflammatory and neuroprotective effects by macrophages loaded with Cl
nanozyme were demonstrated in the mouse model of PD (Figure 9B–9D). 6-OHDA
stereotactically injected into the SNpc produced considerable brain inflammation signified
by upregulated expression of CD11b by microglia within the SNpc, which exhibited a more
amoeboid morphology compared with ramified microglia in PBS-treated mice. By contrast,
treatment of intoxicated mice with BMMs preloaded with Cl-6-BS3 resulted in decreased
levels of CD11b and 50% fewer activated microglia cells compared with 6-OHDA-
intoxicated control animals (Figure 9B & 9D). Furthermore, systemic administration of
nanozyme-preloaded macrophages increased neuronal survival in 6-OHDA-intoxicated mice
(Figure 9C & 9D). The numbers of tyrosine hydroxylase-expressing neurons in the SNpc of
6-OHDA animals treated with nanozyme-preloaded macrophages were significantly greater
(p < 0.05) than those animals intoxicated with 6-OHDA and then injected with PBS. It is
worth noting that empty macrophages as well as nanozyme alone had a subtle but
statistically significant neuroprotective effect in mice with 6-OHDA ic. injections (Figure
9B–9D). We hypothesized that the particular subset of macrophages used in these studies
(differentiated in the presence of MCSF) has a regeneration effect, as reported in [32]. No
significant effect of catalase alone, nanozyme alone, BMMs preincubated with PBS or
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BMMs preloaded with naked catalase was found on microglia activation or neuronal
survival in healthy mice (Figure 9B–9D & Supplementary Figure S9).
Discussion & conclusion
The inability of most potent therapeutics to cross the BBB following systemic
administration necessitates the need to develop unconventional, clinically applicable drug-
delivery systems to treat CNS disorders. Smart, biologically active vehicles are crucial to
accomplish this challenging task. Using inflammatory response cells enables targeted drug
transport and prolonged circulation times, along with reductions in cell and tissue toxicities.
Here, we report the manufacture of new nanoformulations of nanozymes with chemically
stabilized structure and improved loading capacity for the delivery of antioxidants in
macrophages to disease inflamed brain areas.
It is worth noting that the approach for nanoformulation design for cell-mediated delivery
should differ from the injectable formulations. In particular, we demonstrated that the
increasing size of nanoparticles by cross-linking of several protein globules resulted in the
exponentially increased loading capacity in macrophages as well as release from the cell
carriers. This is consistent with the reported earlier studies that particles with approximately
1-µm diameter accumulated at a greater extent (2.6-fold) than smaller drug carriers of 500-
nm diameter in macrophages [36]. Moreover, phagosomes may have different sizes
depending on the size of the particles, which can range from as little as a few hundred
nanometers [37, 38] to dozens of microns [39]. Next, a chemical cross-linking provided
significant protection for the encapsulated enzyme, which remains capable of ROS
decomposition without the need for particle enzyme release. Therefore, Cl nanozyme
demonstrated significantly greater (approximately six-times) enzymatic activity than the
non-Cl formulation. In addition, Cl nanozyme at Z = 6 provided the best protection of
catalase activity against degradation inside the host cells in an in vitro PD model.
Furthermore, the optimal nanozymes released from preloaded macrophages have potent
antioxidant effects in neurons activated with 6-OHDA. This is probably a result of two
separate processes: high catalytic activity of nanozyme released from the cell carriers, and
efficient nanozyme transfer from preloaded macrophages into neurons. This suggests that
macrophages preloaded with optimal structure nanozymes can mitigate oxidative stress
associated with the neurodegenerative process.
The improved protection of Cl nanozymes against degradation in the cell carriers may be
attributed to its intracellular distribution. The confocal images confirmed that a substantial
portion of the block copolymer was dissociated from the non-Cl BIC upon entering
macrophages, and remained in the peripheral areas of the cells. By contrast, all polymer
molecules were colocalized with catalase when Cl nanozyme was used. The role of PEI–
PEG is crucial in the preservation of catalase enzymatic activity in macrophages. According
to our earlier studies, increasing the amount of the block copolymer in the BIC led to an
increase in the endosomal pH, and resulted in better protection of the enzyme [13]. Indeed,
an excess of free amino groups in the BIC nanoparticles at high Z values might buffer
acidification of the endocytic compartments of the cells, thereby inhibiting protease activity
with consequent decreases in catalase degradation [20]. In other words, a positively charged
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block copolymer might delay phagosomal maturation and as a result prevent degradation of
the enzyme in macrophages. Alternatively, and perhaps supplementary to the polycation,
PEG chains in the BIC can sterically protect catalase molecules against degradation by
intracellular proteases. This effect should be more pronounced in the Cl nanozymes that do
not dissociate in the cell compartments. Indeed, a nonbiodegradable linker (BS3) was more
efficient in the preservation of nanozyme activity than a biodegradable one (DTSSP).
Furthermore, the intracellular distribution studies indicate that Cl nanozymes enter fast
through early and late endosomes, and then escape from endosomal compartments, probably
due to the ‘proton sponge effect’, reaching largely the ER and mitochondria. Very few, if
any, Cl nanozyme particles were found in recycling endosomes. By contrast, the non-Cl
nanozyme was localized predominantly in recycled endosomes, as reported earlier [34].
Since macrophages are known to release different neurotoxic agents, including oxidative
metabolites and proinflammatory cytokines, there is a significant concern as to whether the
cell carriers can bring additional inflammation to the disease site. In fact, the BBB
breakdown and entrance of inflammatory response cells to the brain under pathological
conditions was traditionally suggested to have a negative role in secondary tissue
degeneration. A number of therapeutic strategies for CNS neurodegenerative disorders were
based on the prevention of monocyte–macrophage infiltration due to this reason [40].
However, developments in the last few decades began to change this dogma [41]. It has been
demonstrated that macrophages may promote both injury and repair in the sites of CNS
injury [32]. Here, we evaluated whether the cell carriers cause inflammation and neuronal
damage in in vitro and in vivo studies. Our earlier studies and the present work show no
cytotoxic effects in mice upon injection of a particular subset of macrophages differentiated
in the presence of MCSF [12, 29]. We demonstrated here a subtle, but statistically
significant, effect on improved neuronal survival in mice following iv. injection of these
macrophages even without nanozyme. We hypothesized that differentiation of BMMs in the
presence of MCSF resulted in a specific subset of anti-inflammatory (M2) macrophages.
This was confirmed by confocal microscopy showing overexpression of the mannose
receptor in these cells, which is indicative for a M2 subtype. Alternatively activated
macrophages are known to release various factors that promote CNS repair, inducing neural
tissue regeneration and renewal, matrix remodeling, debris clearance and angiogenesis [32].
Therefore, properly differentiated immune cells accumulating in traumatic, degenerative,
ischemic, infectious and autoimmune lesions of the nervous system might provide a
neuroprotective effect, which may further boost the therapeutic effect of cell-mediated drug-
delivery systems.
Finally, we evaluated the potential of optimal Cl nanozymes to attenuate oxidative stress in a
PD murine model. Cl catalase nanozyme administered in macrophages caused prolonged
decreases of neuroinflammation in LPS-intoxicated mice, as demonstrated by IVIS.
Immunohistochemical analysis confirmed systemic administration of macrophages with
nanozyme resulted in a substantial and prolonged attenuation of neuroinflammation (over 5
weeks), and increased neuronal survival in 6-OHDA-intoxicated mice.
The mechanisms of the neuroprotective effects of cell-based catalase nanoformulations are
still not well understood. In fact, immunocytes, mononuclear phagocytes (monocytes,
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macrophages and dendritic cells), lymphocytes and neutrophils, as well as stem cells exhibit
an intrinsic homing property, enabling them to migrate to sites of injury, inflammation and
tumor across the BBB in response to the release of cytokines/chemokines and upregulation
of certain cell surface proteins in the diseased tissues and nearby blood vessels. Even in the
healthy brain, perivascular macrophages, which reside on the parenchymal side of
endothelial cells, originally come from circulating phagocytes, monocytes and macrophages,
and have shown a remarkable capability to cross an intact BBB with an 80% turnover in 3
months [42,43]. It was reported that leukocytes traffic primarily between adjacent
endothelial cells through the junctional complexes (paracellular migration) [44,45] or, in
some cases, even through the endothelial cell itself (transcellular migration) [46]. Under
pathological conditions, the rate of immunocyte transport to the inflamed brain tissues is
further elevated [23,47–52]. Such frequent migration offers a unique opportunity to design
novel cell-based drug formulations, when living cells act as Trojan horses carrying
concealed drug cargoes while migrating across impermeable barriers (the BBB or blood–
tumor barrier) to the sites of disease.
We demonstrated here that GFP-expressing macrophages accumulate in the brain in PD
mice, which is consistent with our previous investigations that reported transport of
fluorescently labeled [12] and luciferase-expressing [29] BMMs in the inflamed mouse
brain. We also showed in this study increases in catalase enzymatic activity in the SNpc
following adoptive transfer of nanozyme-loaded BMMs in PD mice. This confirmed our
previous reports that BMMs preloaded with 125I-labeled [11], 3H-labeled [14] and
fluorescently labeled [12] catalase nanozyme facilitated delivery of catalase to the inflamed
brain. Nevertheless, this Trojan horse effect may not be the one and only mechanism of
macrophage-mediated therapeutic effects. Therefore, several independent processes may
serve to improve nanozyme-loaded macrophage therapeutics. In addition to the targeted
tissue-specific delivery of therapeutics in BMMs [12,14], nanozyme-loaded macrophages
were shown to prolong circulation in the blood, and therefore permit sustained release of
catalase, allowing the enzyme to enter the brain, independent of carrier cells (‘depot effect’)
[12,14]. Furthermore, catalase released from the macrophages in the liver and spleen can
suppress peripheral leukocyte activation and protect nigrostratial neurons at a distance [12].
Finally, drug-loaded BMMs can transfer catalase nanoparticles to brain microvessel
endothelial cells and increase BBB penetration and ROS decomposition [34]. We reported
that such events occur through endocytosis-independent mechanisms, including fusion of
cellular membranes, formation of macrophage bridging conduits, (i.e., filopodia and
lamellipodia) that stretch to the neighbouring cells, and nanozyme incorporation into
exosomes [28]. These extracellular vesicles released from preloaded macrophages may
facilitate nanozyme transfer from carrier cells to target recipient cells [34]. Unfortunately, at
this stage of understanding, we cannot discriminate which mechanism is the most important
for the therapeutic effects of cell-based nanoformulations. A comprehensive examination
and detailed understanding of these mechanisms would be of great value in designing
strategies for cell-mediated drug delivery.
Overall, these studies demonstrated the feasibility of the therapeutic approach using cell-
mediated catalase delivery for neuroprotection. Macrophages are attractive drug carriers due
to their natural mobility, ability to efficiently engulf particles, penetrate the BBB and reach
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the site of neuropathology. The ultimate goal is to create such nanozymes that can be loaded
to the cell carriers in the patient bloodstream and delivered by active targeted transport to the
brain with inflammation.
Future perspective
Using cells as delivery vehicles enables targeted drug transport and prolonged circulation
times along with reductions in cell and tissue toxicities. Immunocytes are highly mobile and
capable of cell-to-cell transmission of drug-laden nanoparticles. Therefore, such systems
represent a novel disease-combating strategy being applied to a spectrum of human
disorders. However, this is not a simple task. The formulation design should provide high
drug loading in cell carriers, efficient drug protection against degradation inside the cell
carriers and sustained release at the disease site. In addition, the cell carriers should migrate
in substantial quantities and be safe for the organism. Nevertheless, using optimal drug
nanoformulations along with a specific subtype of ‘alternately activated’ anti-inflammatory
macrophages opens the opportunity to exploit immune cells as Trojan horses for drug
delivery.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Cell-based drug delivery platform
▪ Macrophages preloaded with nanoformulated catalase, ‘nanozyme’, offer a
new delivery system for active targeted transport of the antioxidant to the
inflamed brain.
Nanozyme manufacture
▪ A formulation design of optimal particles delivered in macrophages differs
from a common approach for injectable drug nanoformulations. They should
have a relatively large size, be stabilized by excess of nonbiodegradable
linker and be vectorized to the cell carriers.
Using a specific subtype of cell carriers
▪ Anti-inflammatory ‘alternatively activated’ macrophages that promote CNS
repair should be used for drug delivery.
Macrophages accumulate in mouse inflamed brain
▪ Systemically administered macrophages were able to cross the blood–brain
barrier and reach the brain tissues with inflammation.
Therapeutic effects of nanozyme-loaded bone marrow-derived macrophages
▪ Nanozyme loaded in macrophages reduced neuroinflammatory responses and
increased neuronal survival in mice, providing a translational link of these
formulations to the clinic.
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Figure 1. Nanozyme’s structure stabilization
BICs spontaneously form in aqueous solution as a result of electrostatic coupling of catalase
and a cationic block copolymer, poly(ethyleneimine)–polyethylene glycol. The obtained
polyion complex, nanozyme, was further stabilized by cross-linking with an excess of
biodegradable and nonbiodegradable linkers. BIC: Block ionomer complex.
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Figure 2. Effect of nanozyme size on loading and release from RAW 264.7 macrophages
Uptake: the cells were treated for 2 h with different 3H-labeled cross-linked nanozymes
(charge ratio = 2–9). Macrophages were then washed, solubilized in Triton™ X-100
(Sigma-Aldrich, MO, USA; 1%) and the amount of accumulated catalase was measured by
radioactivity counter. Release: the cells were loaded with different 3H-labeled nanozymes as
described before, washed with phosphate-buffered saline and incubated with catalase-free
media for 2 h. Concomitant media was then collected and the amount of released catalase
was accounted for by radioactivity counter. Results from eight wells (± standard error of the
mean) demonstrated an exponential increase in accumulation (squares) and release (circles)
of nanozyme with the increased size.
*p < 0.05.
**p < 0.005.
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Figure 3. Nanozyme cross-linking preserves catalase enzymatic activity in RAW 264.7
macrophages
(A) ‘Naked’ catalase, or different catalase formulations: non-Cl nanozyme (non-Cl-6), Cl
nanozyme with biodegradable linker (Cl-6-DTSSP), or Cl nanozyme with nonbiodegradable
linker (Cl-6-BS3) were loaded into RAW 264.7 macrophages for 2 h. The cells were then
washed and incubated with catalase-free media for various periods of time. Following
incubation, the concomitant media was collected, and the activity of catalase released from
preloaded macrophages was accounted for by spectrophotometry. Cross-linking of
nanozymes considerably increased the stability of catalase against degradation in the cells,
especially at longer time intervals. (B) Different catalase nanozymes (charge ratio = 2 and 6)
were loaded into RAW 264.7 macrophages for 2 h. The cells were then washed and
incubated in Kreb’s-Ringer buffer for 24 h. In parallel, Cath.A neurons were either
incubated with assay buffer (PBS), or stimulated with 200 µM 6-OHDA to produce reactive
oxygen species for 24 h. The supernatants collected from macrophages with the released
enzyme were supplemented with Amplex® Red (Life Technologies, NY, USA) and
horseradish peroxidase solutions and added to the activated neuronal cells. Control activated
neurons were incubated with concomitant media from nonloaded macrophages. The amount
of hydrogen peroxide produced by neuronal cells and decomposed by catalase released from
macrophages was detected by fluorescence. The catalase activity was best protected by Cl
nanozyme with a high excess of the block copolymer (Cl-6-BS3) released from
macrophages. (A & B) Data represent the mean ± standard error of the mean (n = 4).
Statistical significance of nanozyme activity compared with (A) catalase alone or (B) media
collected from empty macrophages is shown by asterisks: *p < 0.05, **p < 0.005. 6-OHDA:
6-Hydroxydopamine; BS3: Bis-(sulfosuccinimidyl)suberate sodium salt; Cl: Cross-linked;
DTSSP: 3,3’-Dithiobis-(sulfosuccinimidyl propionate).
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Figure 4. Macrophage differentiation toward alternatively activated (anti-inflammatory)
macrophages
(A) RAW 264.7 macrophages were cultured in the presence of (i) IFN-γ and LPS for the M1
proinflammatory subtype or (ii) IL-4 for the M2 anti-inflammatory subtype, (iii) or 100
µg/ml MCSF for 2 days as described in the ‘Materials & Methods’ section. The cells were
then stained with a mixture of (A,i,a–A,iii,a) antibodies to CD 86 and (A,i,b–A,iii,b)
mannose receptors for the M1 and M2 phenotype, respectively, and examined by confocal
microscopy. (A,i) Macrophages differentiated in the presence of IFN-γ/LPS showed high
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expression of CD 86, but low, if any, expression of the mannose receptor, indicating the
classically activated M1 subtype. (A,ii & A,iii) By contrast, cells differentiated in the
presence of IL-4 or MCSF showed high expression of the mannose receptor, and low
expression of CD 86, which is attributed to M2 macrophages. (B) A response of different
subtypes of macrophages to proinflammatory conditions. RAW 264.7 macrophages cultured
in the absence of MCSF demonstrated significant increases in ROS production in response
to stimulation of IFN-γ/LPS. By contrast, macrophages cultured in the presence of MCSF
did not demonstrate increased reactive oxygen species production, suggesting that a
particular subset of the cell carriers (M2 subtype) would not cause addition inflammation in
the brain upon arrival. Data represent the mean ± standard error of the mean (n = 6).
LPS: Lipopolysaccharide; MCSF: Macrophage colony-stimulating factor.
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Figure 5. Intracellular distribution of catalase and block copolymer in bone marrow-derived
macrophages
Different nanozymes were prepared with Alexa Fluor® 488-labeled catalase (Invitrogen,
CA, USA; green) and rhodamine isothiocyanate-labeled polymers (poly(ethyleneimine)
[PEI] or PEI–polyethylene glycol [PEG]; red). Bone marrow-derived macrophages were
incubated for 2 h with (A) catalase-alone, or different nanozyme formulations: (B) non-
cross-linked (non-Cl) PEI/catalase; (C) non-Cl PEI–PEG/catalase (non-Cl-6); or (D) Cl
PEI–PEG/ catalase (Cl-6-bis-(sulfosuccinimidyl)suberate sodium salt), washed with
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phosphate-buffered saline, and then visualized by confocal microscopy. (D) Stabilization of
nanozyme structure by cross-linking resulted in practically total colocalization of the
polymer and catalase inside macrophages. (C) PEG corona in non-Cl nanozyme partially
prevented block ionomer complex dissociation. (B) The non-Cl block ionomer complexes
with PEI polymer were completely dissociated.
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Figure 6. Nanozyme intracellular trafficking in macrophages
Alexa Fluor® 680-labeled catalase (Invitrogen, CA, USA; red) was used to obtain cross-
linked 6-bis-(sulfosuccinimidyl)suberate sodium salt. Live human monocyte-derived
macrophages were incubated with cross-linked nanozyme for different times, and stained
with: (A) LysoTracker® Green (Life Technologies, NY, USA; 150 nM), (B) ER-Tracker™
Green (Life Technologies; 1 µM), or (C) MitoTracker® Green (Life Technologies; 150 nM).
The macrophages were incubated for (A,i, B,i & C,i) 5 min, (A,ii, B,ii & C,ii) 15 min and
(A,iii, B,iii & C,iii) 30 min. Colocalization of nanozyme (red) and compartment staining
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(green) is manifested as yellow. Nanozyme accumulated first in acidified compartments and
then reached mitochondria and endoplasmic reticulum. Refer also to Supplementary Table
S3 for quantitative colocalization. The percentages in the bottom left hand of every image
are the percentages of colocalization of nanozyme (red) and the compartment staining
(green) specific for each slide, which is manifested in yellow colour.
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Figure 7. Effect of nanozyme cross-linking on macrophage trafficking
Human monocyte-derived macrophages were incubated with fluorescently labeled cross-
linked and non-cross-linked nanozymes for 1 h, stained with different markers to specific
intracellular compartments, and a percentage of nanozyme colocalization with these markers
was evaluated using confocal microscopy images. Data represent the mean ± standard error
of the mean (n = 40). Stabilization of nanozyme structure by cross-linking of nanoparticles
drastically altered trafficking and intracellular localization in macrophages, shifting
distribution from recycling and late endosomes to endoplasmic reticulum, mitochondria and,
in part, lysosomes. Data for non-cross-linked nanozymes were reported in [34].
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Figure 8. Recruitment of green fluorescent protein-expressing RAW 264.7 macrophages to the
substantia nigra pars compacta in 6-hydroxydopamine-intoxicated mice
(A)Macrophages were transduced with green fluorescent protein (GFP) firefly luciferase
virus and selected against katamycin. BALB/c mice were intracranially injected with 6-
hydroxydopamine into the substantia nigra pars compacta, as described in the ‘Materials &
Methods’ section. A total of 21 days later, the animals were injected into the intrajugular
vein with GFP-expressing RAW 264.7 macrophages (green; 5 × 106 cells/ mouse in 100 µl).
A total of 24 h later, the mice were sacrificed, and perfused with phosphate-buffered saline
and 4% paraformaldehyde. (B) The brains were frozen, sectioned with a cryostat (10 µm
thick) and examined by confocal microscopy (60× magnification). (C) Healthy mice without
brain inflammation (with phosphate-buffered saline intracranial injections) were used as a
control group. Slides were stained with primary antibodies to CD11b, a marker for
macrophages, and secondary fluorescently labeled anti-mouse-IgG-atto 647N (red).
Colocalization of GFP-expressing macrophages and CD11b antibodies, manifested in
yellow staining, confirmed the presence of significant amounts of the genetically modified
cells in the intoxicated brain. (C) No fluorescence in the healthy brain was found, indicating
that systemically administered RAW 264.7 macrophages did not cross the blood–brain
barrier in the absence of brain inflammation.
Klyachko et al. Page 32






















Figure 9. Effect of cross-linked nanozyme loaded into macrophages on the reduction of
neuroinflammation and increase in neuronal survival in mice with brain inflammation
(A,i)C57Bl/6 mice with LPS-induced encephalitis were injected intravenously with
macrophages (5 × 106/mouse in 100 µl PBS) preloaded with cross-linked nanozyme (bis-
(sulfosuccinimidyl)suberate sodium salt, charge ratio = 6; 2 mg/ml catalase) or PBS. (A,ii)
Image visualization and infrared spectroscopy images over 20 days were taken 10 min after
intraperitoneal injection of a XenoLight™ RediJect probe (Caliper LifeSciences, MA,
USA). (A,ii,a) Whole body images and (A,ii,b) images of the mouse head for the
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corresponding time. The chemiluminescent signal was quantified and presented as radiance
ratios of treated animal versus 24 h after LPS injection at various times. Macrophages
preloaded with the cross-linked nanozyme caused prolonged decreases of
neuroinflammation in LPS-intoxicated mice. Data represent mean ± standard error of the
mean (n = 5). The statistical significance of inflammation levels compared with control
LPS-intoxicated mice is shown by asterisk: *p < 0.05. (B–D) C57Bl/6 mice were
intracranial injected with 6-OHDA. A total of 48 h later, animals were intravenously
injected with macrophages preloaded with catalase alone, cross-linked nanozyme alone,
empty macrophages or macrophages preloaded with cross-linked nanozyme, and 5 weeks
later they were sacrificed and midbrain slides were stained for expression of (B) Mac1+, a
marker for activated microglia or (C) tyrosine hydroxylase, a marker for dopaminergic
neurons. (D) Quantification of microglial activation and neuronal survival. Values represent
mean ± standard error of the mean (n = 6), and p < 0.05 compared with †: PBS (healthy
controls); †: 6-ODHA (PD mouse model); §: catalase alone (in 6-OHDA intoxicated mice);
and ¶: empty macrophages (in 6-OHDA-intoxicated mice). Selected images of several
additional control groups are presented on Supplementary Figure S9. Whereas 6-OHDA
treatment caused significant microglia activation and neuronal loss, administration of
nanozyme-preloaded macrophages significantly decreased oxidative stress and increased
neuronal survival. The administration of empty M2 macrophages slightly decreased
microglia activation, and increased the number of dopaminergic neurons in mice with brain
inflammation. 6-OHDA: 6-Hydroxydopamine; BMM: Bone marrow-derived macrophage;
LPS: Lipopolysaccharide; PBS: Phosphate-buffered saline; PD: Parkinson’s disease
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Table 1
Description of nanozymes.
Sample ID Nanoparticle Z Cross-linker
Catalase Catalase alone 0 None
Non-Cl-2 Non-Cl BIC 2 None
Non-Cl-6 Non-Cl BIC 6 None
Cl-2-BS3 Cl BIC 2 BS3
Cl-4-BS3 Cl BIC 4 BS3
Cl-6-BS3 Cl BIC 6 BS3
Cl-9-BS3 Cl BIC 9 BS3
Cl-9-DTSSP Cl BIC 6 DTSSP
BIC: Block ionomer complex; BS3: Bis-(sulfosuccinimidyl)suberate sodium salt; Cl: Cross-linked; DTSSP: 3,3’-Dithiobis-(sulfosuccinimidyl
propionate); ID: Identification; Z: Charge ratio.
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Table 2
Hydrodynamic diameter of nanozymes measured by dynamic light scattering.
Nanozyme Z Deff (nm) PDI Zeta-potential (mV)
Catalase alone 0 12.5 ± 0.1 0.10 −10.7
Non-Cl-2 2 13.9 ± 0.1 0.20 −0.8
Non-Cl-6 6 24.2 ± 0.1 0.20 −0.1
Cl-2-BS3 2 79.0 ± 0.2 0.20 −7. 0
Cl-4-BS3 4 118.0 ± 0.2 0.20 −4.9
Cl-6-BS3 6 175.5 ± 0.2 0.20 −1. 3
Cl-9-BS3 9 161.3 ± 0.2 0.09 −1. 8
Cl-6-DTSSP 6 152.7 ± 0.2 0.20 −4.3
The Deff values represent the mean ± standard error of the mean of three separate measurements. BS3: Bis-(sulfosuccinimidyl)suberate sodium
salt; Cl: Cross-linked; Deff: Hydrodynamic diameter; DTSSP: 3,3’-Dithiobis-(sulfosuccinimidyl propionate); PDI: Polydispersity index; Z: Charge
ratio.
Nanomedicine (Lond). Author manuscript; available in PMC 2014 September 11.
